Clinical Trials
34 trialsIIT PH1 KDS-1001 in Patients With CML
Duke University
Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor
University of Southern California
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
Indiana University
2019-KOE-001
Baptist Health South Florida
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
Medigene AG
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
University of Michigan Rogel Cancer Center
Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer
City of Hope Medical Center
Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies
Bellicum Pharmaceuticals
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Fred Hutchinson Cancer Center
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS
Bio-Path Holdings, Inc.
IDEAL-E
Asan Medical Center
Providing Access to Cord Blood Units for Transplants
National Institutes of Health Clinical Center (CC)
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
M.D. Anderson Cancer Center
Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes
M.D. Anderson Cancer Center
StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Masonic Cancer Center, University of Minnesota
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
MACS1881
Novartis
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Sheba Medical Center
Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders
Shandong University
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
Bristol-Myers Squibb
Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia
Mayo Clinic
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
University of Michigan Rogel Cancer Center
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
Fred Hutchinson Cancer Center
PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation
M.D. Anderson Cancer Center
Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer
Vanderbilt-Ingram Cancer Center
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Columbia University
KGF Haplo Allo
European Society for Blood and Marrow Transplantation
Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy
Bristol-Myers Squibb
A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)
New Mexico Cancer Research Alliance
Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia
Hadassah Medical Organization
A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia
University of Cincinnati